Abstract 3213
Background
Photodynamic therapy (PDT) is one of actively developing modalities of cancer treatment. During PDT procedure systemically injected photosensitizer molecules are activated by laser irradiation in tumor location leading to generation of singlet oxygen which induces cytotoxic effect. In modern clinical practice PDT uses continuous wave irradiation. In such mode fast depletion of molecular (triplet) oxygen in tissue occurs leading to reduction of PDT efficiency. Previously we have shown that photodynamic treatment using pulse mode irradiation regimens could be more efficient in damaging tumor cells than standard PDT due to reoxygenation (Klimenko et. al., Photodiagnosis Photodyn Ther., 2016). In present study we have evaluated specially designed pulse mode PDT regimes on tumor model in vivo.
Methods
PDT pulse mode irradiation regimens were designed using physics and mathematical modelling. BALB/c male mice were subcutaneous injected into right flanks with CT26 murine colon carcinoma cells. At day ten after inoculation mice were randomized into 3 groups with 10 animals in each (control group, PDT at continuous wave irradiation mode – CW group, PDT at pulse irradiation mode – PM group) and PDT was made. The RadachlorinⓇ photosensitizer and «Lahta-Milon» semiconductor laser (662 nm) were used. After treatment the tumor size was estimated every two days. All experiments were performed in accordance with the animal ethics guidelines.
Results
We have designed new pulse mode irradiation regimens of PDT. We have shown that antitumor efficiency of PDT at pulse irradiation mode is much better than one at standard continuous wave irradiation mode. Median survival after day of treatment was 14 days in control group, 16 days in CW group and 28 days in PM group. In PM group 5 animals had total regress of tumor and progression free survival till the end of experiment (100 days after treatment) compared with only 1 animal in CW group. Thus, we can suggest that overall survival should be much higher in PM group.
Conclusions
We have demonstrated that PDT using pulse mode irradiation regimens is much more effective that PDT using standard regimens and leads to higher progression free and overall survival in mice with CT26 colon carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract